Organon & Co reports results for the quarter ended June 30 - Earnings Summary

• Organon & Co OGN.N reported quarterly adjusted earnings of $1.00​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $1.12. The mean expectation of seven analysts for the quarter was for earnings of 95 cents per share. Wall Street expected results to range from 90 cents to 99 cents per share.

• Revenue fell 0.8% to $1.59 billion from a year ago; analysts expected $1.55 billion.

• Organon & Co's reported EPS for the quarter was 56 cents​.

• The company reported quarterly net income of $145 million.

• Organon & Co shares had fallen by 0.1% this quarter and lost 35.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Organon & Co is $11.00, about 12.1% above its last closing price of $9.67

This summary was machine generated from LSEG data August 5 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)